Product for Licensing | 药时代DrugTimes

首页
药资讯
视频专区
精彩活动
BD投融资平台
药时代知识宝库
All English

登录注册

Product for Licensing

Filter by Indication

Oncology
Immunology
CNS/Pain
Anti infection/viral
Digestion/Endocrinology/Metabolism

Oncology

【Product for Licensing】A Highly Differentiated EGFR x HER2 Bispecific ADC for Targeted Therapy of Multiple Types of Solid Tumors

2024年11月12日 1.0K0
Oncology

【Product for Licensing】A Highly Differentiated B7-H3 x PSMA Bispecific ADC, Potentially Best-in-Class, for the Treatment of mCRPC

2024年11月12日 9790
Antibody

【Product for Licensing】High Binding Affinities and Potent Anti-tumor Efficacy Nectin4-CD137 BsAb

2024年8月1日 2890
Antibody

【Product for Licensing】A FIC Her2xCD47xCD16a Tri-specific Antibody for Treating Her2 High and Low or Negative Cancers

2024年7月26日 9750
ADC/XDC

Novo and Eli Lilly’s favored ADC payload, are you interested? | DrugTimes BD Project

2024年7月22日 3520
ADC/XDC

【Product for Licensing】ANTI-CDCP1 mAb and ADC

2024年6月28日 2590

点击查看更多

Skin and Otolaryngology
Cardiovascular
Respiratory
Urology/Reproduction
Others

Filter by Stage

PCC
Pre-clinical
IND
Phase I
Phase II
Phase III
NDA
Approval

Immunology

密码保护：【Product for Licensing】A New Class of IRAK4 PROTAC with Best-in-Class Potential

2024年8月13日 3280
Antibody

【Product for Licensing】High Binding Affinities and Potent Anti-tumor Efficacy Nectin4-CD137 BsAb

2024年8月1日 2890
PCC

【Product for Licensing】A Highly Differentiated IL-2- Fc-IFN-α Fusion Protein for Cancer Combination Therapies

2024年7月30日 2660
Antibody

【Product for Licensing】A FIC Her2xCD47xCD16a Tri-specific Antibody for Treating Her2 High and Low or Negative Cancers

2024年7月26日 9750
ADC/XDC

Novo and Eli Lilly’s favored ADC payload, are you interested? | DrugTimes BD Project

2024年7月22日 3520
Antibody

密码保护：【Product for Licensing】 A bispecific antibody targeting TL1A and IL23p19

2024年7月17日 2110

点击查看更多

Filter by Modality

Small Molecule
Peptide
Antibody
ADC/XDC
Protein
Protac
CGT
Vaccine
Others

Immunology

密码保护：【Product for Licensing】The Phase I completed TYK2 Allosteric Inhibitor with better selectivity, solubility and greater safety window

2024年7月22日 3080
ADC/XDC

Novo and Eli Lilly’s favored ADC payload, are you interested? | DrugTimes BD Project

2024年7月22日 3520
Immunology

【Product for Licensing】The Phase II Small Molecule targeting IL-17 & IL-4Ra solves unmet medical needs in Psoriasis and Atopic Dermatitis

2024年7月19日 2820
Immunology

【Product for Licensing】The Phase I ready Small Molecule with FIC potential in IBD

2024年7月18日 2300
Phase II

密码保护：【Product for Licensing】Phase II IPF Candidate with Potent efficacy and better safty and PK property

2024年7月17日 2130
Immunology

【Product for Licensing】Better Clinical Compound for Pulmonary IPF & PPF & ILD

2024年7月2日 1880

点击查看更多

TOP VIEWS

15.7K

A long-acting anti-TL1A mAb with best-in-class potential
$2.02B deal on preclinical small molecule lipoprotein(a) inhibitor! Are you interested in a similar product? We can help!

3.2K
【Product for Licensing】A Highly Differentiated EGFR x HER2 Bispecific ADC for Targeted Therapy of Multiple Types of Solid Tumors

1.0K
【Product for Licensing】A Highly Differentiated B7-H3 x PSMA Bispecific ADC, Potentially Best-in-Class, for the Treatment of mCRPC

979
【Product for Licensing】A FIC Her2xCD47xCD16a Tri-specific Antibody for Treating Her2 High and Low or Negative Cancers

975

首页
药资讯
精彩活动
BD投融资平台
药时代知识宝库
联系我们
免责声明 Disclaimer

Copyright Reserved © 药时代 DRUGTIMES 版权所有请勿转载

沪ICP备17025211号-1

本站部分文字及图片来源于网络，如侵犯到您的权益，请及时告知并联系 contact@drugtimes.cn，本站将及时处理或撤换，特此声明。

公众号

分享本页

返回顶部

药时代知识宝库

2024肝病新药联盟年会暨减重新药论坛，欢迎报名！